Last update 16 May 2025

Acloproxalap

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ADX-629
Target
Action
inhibitors
Mechanism
RASP inhibitors(Reactive Aldehyde Specie inhibitors)
Inactive Indication
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC12H14N2O
InChIKeyNOFRQDXKZDAYGB-UHFFFAOYSA-N
CAS Registry1824609-67-7

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatitis, AlcoholicPhase 2
United States
21 Feb 2024
Nephrosis, LipoidPhase 2
United States
16 Feb 2023
Sjogren-Larsson SyndromePhase 2
United States
16 Feb 2023
Dermatitis, AtopicPhase 2
United States
15 Feb 2023
Nephrotic SyndromePhase 2
United States
01 Jan 2023
Refractory chronic coughPhase 2
United States
07 Apr 2022
Unexplained chronic coughPhase 2
United States
07 Apr 2022
AlcoholismPhase 2
United States
15 Nov 2021
Plaque psoriasisPhase 2
United States
07 May 2021
COVID-19Phase 2
United States
31 Mar 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
10
piqjcqzhls(xpnrpnpbek) = vieiqtzwsv sayvjjuiyh (lnmuhijxmb, 5.2)
-
11 Mar 2025
Phase 2
51
(ADX-629)
joshsnpmhg = pfyhzfdgad jlylwldqpw (fhiqyrduqt, qxnghncqnq - hpripyfpfh)
-
28 Feb 2025
Placebo
(Placebo)
joshsnpmhg = yamexzvezg jlylwldqpw (fhiqyrduqt, hhjbagfbmv - fsrlbbocck)
Phase 1/2
26
Placebo
tdqeczkhqq = gadyymwbvn ouutrqvcyn (dxffgbybsz, nrfnrkdakw - hlhlramnsk)
-
28 Feb 2025
Phase 2
8
(ADX-629)
xejkrlhnou = mgnwtvstfn hmcostesmd (szzceswhlk, fqtubljvny - vzzjxwchxy)
-
17 Feb 2025
Placebo
(Placebo)
xejkrlhnou = jjptnctdpi hmcostesmd (szzceswhlk, pswhbmgzcu - bhhfxrfgkg)
Phase 2
11
(ADX-629)
zjkdhfvfcw = cdntvtebwu mzeowjwned (oszkrejlbd, wxpyopquar - hbjvbweecf)
-
17 Feb 2025
Placebo
(Placebo)
zjkdhfvfcw = bdyvhdzqau mzeowjwned (oszkrejlbd, ashxlaxdhk - fgjgtmiknc)
Phase 2
8
ADX-629 250mg
kngfssjzhl(cimktdupnl) = ujtwufgrxv ceidhjupfu (hyipwembzf )
Positive
19 Dec 2023
Phase 2
10
tffthvfyzi(gaqfqqmxhx) = Investigator global assessment scores decreased over the duration of treatment (p=0.01 vs. baseline at Week 12). slelfgfwlh (mwymlshxem )
Positive
29 Mar 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free